In Vitro Toxicology Testing Market is projected to reach USD 17.1 billion by 2028 from an estimated USD 10.8 billion in 2023, at a CAGR of 9.5% during the forecast period. The major factors driving the growth of this in vitro toxicology testing include the public opposition to animal testing, the emergence of promising new toxicology testing technologies, and increased research and development investment for early toxicity detection.

The In Vitro Toxicology Testing industry is poised for a transformative evolution in the near future, driven by advancements in technology, regulatory shifts, and an increasing emphasis on ethical and efficient alternatives to traditional animal testing methods. With the development of more sophisticated cell culture models, organ-on-a-chip systems, and high-throughput screening techniques, in vitro testing is set to provide more accurate, cost-effective, and rapid assessments of chemical and pharmaceutical safety. Additionally, the growing global awareness of animal welfare concerns and the tightening of regulatory requirements will further accelerate the adoption of in vitro toxicology approaches, making them a central pillar of drug development, chemical safety assessments, and risk management strategies across diverse industries.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209577065

Browse in-depth TOC on “In Vitro Toxicology Testing Market”
392 – Tables
52- Figures
430 – Pages

Key Market Players of In Vitro Toxicology Testing Industry:

Key players in the in vitro toxicology testing market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), SGS SA (Switzerland), Bio-Rad Laboratories, Inc. (US), Evotec SE (Germany), Promega Corporation (US), Catalent, Inc. (US), Agilent Technologies, Inc. (US), Intertek Group plc (UK), Revvity (US), Inotiv (US), BioIVT (US), Lonza (Switzerland), Creative Biolabs (US), Shanghai Medicilon Inc. (China), Creative Bioarray (US), Aragen Life Sciences Ltd. (India), Enzo Biochem Inc. (US), Microbac Laboratories, Inc. (US), Vimta Labs Ltd. (India), Pacific BioLabs Inc. (US), and MB Research Laboratories (US).

In Vitro Toxicology Testing Market Dynamics:

Drivers:

1. Growing public resistance against animal testing
2. Technological advancements
3. Research and development efforts aimed at early-stage toxicity detection

Restraints:

1. Resistance of certain regulatory bodies to embrace alternative approaches in toxicology testing
2. Failure to establish intricacies of in vivo conditions
3. Lack of in vitro models to study complex endpoints

Opportunities:

1. Growing focus on drug discovery and personalized medicine using in vitro methods
2. Increasing number of toxicology databases
3. Increasing focus on predictive toxicology

Challenge:

1. Lack of data availability and validation
2. Complexity in data analysis and management

Request Free Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=209577065

The consumables segment accounted for the largest share by product & service in the In vitro toxicology testing market in 2022.

By product and service, the In vitro toxicology testing market has been further categorized as consumables, assays, equipment, software, and services. Consumables accounted for the largest share of the in vitro toxicology testing market in 2022. The large share of this segment can be attributed to the increasing demand for high-quality reagents and the repeated use of media and reagents in in vitro toxicology studies. Additionally, the growing R&D activities in the pharmaceutical industry and the increased initiatives by governments in various countries to strengthen their product safety assessment capabilities are supporting the growth of this market.

The organ toxicity segment is expected to grow at a higher rate during the forecast period.

Based on the toxicity endpoints and tests, the in vitro toxicology testing market has been segmented into absorption, distribution, metabolism, and excretion (ADME), skin irritation, corrosion, and sensitization, genotoxicity, cytotoxicity, ocular toxicity, organ toxicity, phototoxicity, dermal toxicity, and other toxicity endpoints & tests. In 2022, the ADME segment accounted for the largest share of the in vitro toxicology testing market. However, the organ toxicity segment is expected to grow at a higher growth rate during the forecast period of 2023-2028. This can be attributed to increasing regulatory demands for safety assessment and reducing animal testing, continuous advancements in cell culture and tissue engineering technologies, and increasing drug development needs.

The pharmaceutical & biopharmaceutical segment accounted for the largest share of the industry segment in the in vitro toxicology testing market in 2022.

Based on industry, the in vitro toxicology testing market has been segmented into pharmaceutical & biopharmaceutical, consumer care, food, and other industries (including chemical and medical device industries). In 2022, the pharmaceutical & biopharmaceutical industry segment accounted for the largest share of the in vitro toxicology testing market. One of the major factors driving the growth of this segment is the mandate of preclinical safety assessment for the marketing approval of pharmaceutical products. Additionally, the rising investments in discovering new ways to construct molecules to study genetics and proteins and the increasing focus on reducing economic losses due to drug failures in the late stage are expected to increase the demand for in vitro tests to screen potentially toxic molecules during drug development.

The cell culture technologies segment accounted for the largest share of the technologies segment in the in vitro toxicology testing market in 2022.

Based on the technologies, the in vitro toxicology testing market has been segmented into cell culture, high-throughput screening, and toxicogenomics. In 2022, cell culture technologies accounted for the largest share. This can be attributed to the fact that it is the most preferred technique for toxicity testing owing to its capability of mimicking in vivo conditions. Cell and tissue-based technologies are commonly employed for in vitro toxicology testing in pharmacology. Cell cultures, either bacterial or mammalian, can express the same genes and proteins as their in vivo counterparts. Their ability to produce similar testing environments is one of the major factors driving the growth of this segment.

The Europe region catered for the largest share of the in vitro toxicology testing market in 2022.

The in vitro toxicology testing market is segmented into North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), and the Middle East and Africa (MEA). The European region is witnessing increasing investments to develop biologics and advanced dosage forms, with the impending patent expiration of several blockbuster drugs. The need to reduce the time and cost incurred to bring a drug to market—roughly 10 to 12 years, has contributed to the demand for in vitro toxicology testing of drugs.

Recent Developments:

• In March 2023, Agilent Technologies, Inc. (US) acquired e-MSion (US). Through this acquisition, Agilent will integrate the e-MSion’s ExD cell into its portfolio of advanced workflows, instruments, and analytical solutions for biotherapeutic characterization and development.
• In January 2023, Eurofins Scientific expanded its presence in India with the establishment of a new, fully equipped, state-of-the-art laboratory campus in Genome Valley, Hyderabad. The lab will support pharma and biotech companies in the areas of synthetic organic chemistry, analytical R&D, bioanalytical services, in vivo pharmacology, safety toxicology, and formulation R&D.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=209577065

In Vitro Toxicology Testing Market Advantages:

• Ethical Considerations: In vitro testing methods are more humane and align with ethical concerns by reducing or eliminating the need for animal testing, thereby reducing harm to animals.
• Cost Efficiency: In vitro testing is often more cost-effective than in vivo testing, as it requires fewer resources, less time, and lower maintenance expenses.
• Rapid Results: In vitro tests can deliver results more quickly, allowing for faster decision-making in drug development, chemical safety assessments, and other applications.
• High Throughput: In vitro testing methods can be automated and conducted at a high throughput, making them suitable for screening large numbers of compounds or chemicals efficiently.
• Reduced Variability: In vitro tests offer greater control over experimental conditions, minimizing the variability often associated with in vivo tests.
• Human-Relevant Data: In vitro models can be designed to mimic human biology more closely, providing more relevant data for predicting human responses to drugs and chemicals.
• Reduced Safety Risks: In vitro testing reduces the potential risks associated with handling and testing in live animals, improving laboratory safety.
• Regulatory Acceptance: Regulatory agencies increasingly accept and encourage in vitro toxicology testing data for safety assessments, streamlining the approval process for pharmaceuticals and chemicals.
• Environmental Benefits: Reduced animal testing leads to fewer ecological impacts, such as reduced use of laboratory animals and fewer waste disposal concerns.
• Adaptability: In vitro testing can be tailored to specific research needs, enabling customization for different applications and industries.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: sales@marketsandmarkets.com